Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.56 |
| ▸ | CCR2 | P41597 | 8/20 | 0.55 |
| ▸ | RBP4 | P02753 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205141 | 0.78 | HSD11B1 (0.63) | HSD11B1KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL16801592 | 0.77 | KDM4E (0.85) | HSD11B1KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL5705116 | 0.76 | KDM4E (0.78) | HSD11B1KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL5202689 | 0.75 | HSD11B1 (0.67) | HSD11B1KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL27201572 | 0.75 | HSD11B1 (0.64) | HSD11B1KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL14032692 | 0.75 | RBP4 (0.57) | KDM4EALDH1A1RBP4CYP2D6CYP2C19 | |
| SCHEMBL25406211 | 0.74 | CCR2 (0.53) | HSD11B1KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL16801948 | 0.74 | KDM4E (0.70) | HSD11B1KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL13853726 | 0.74 | KDM4E (0.74) | HSD11B1KDM4EBRD4ALDH1A1POLB | |
| SCHEMBL23951533 | 0.73 | NPC1 (0.59) | KDM4EALDH1A1POLBCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258862-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258862-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2007027532-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258862-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | LDLR, APOB, FFAR1 | HSD11B1 696/4885KDM4E 4844/4885BRD4 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.